Inhibition of tau phosphorylation: A new therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 10, 2000, Pages 1519-1527

  Castro, A ^a   Martinez, A ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Alzheimer's disease; CDK5 p35 inhibitors; GSK 3 inhibitors; Tau protein kinase inhibitors

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; AMYLOID BETA PROTEIN; BISINDOLE DERIVATIVE; BISINDOLYLMALEIMIDE; CASEIN KINASE; CASEIN KINASE I; CASEIN KINASE II; CYCLIN DEPENDENT KINASE INHIBITOR; GF 1092203 X; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULATIMIDE; HYDROXYFLAVONE DERIVATIVE; HYMENIALDISINE; INDENOPYRROLOCARBAZOLE DERIVATIVE; INDIRUBINE; INDOLOBENZAZEPINONE DERIVATIVE; INDOLOCARBAZOLE DERIVATIVE; KENPAULLONE; LITHIUM; MALEIMIDE DERIVATIVE; PROPANONE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN P53; PURINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ASCIDIACEA; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DEPRESSION; DRUG CONFORMATION; DRUG EFFECT; DRUG INDICATION; DRUG ISOLATION; DRUG SCREENING; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOMA; HUMAN; MICROTUBULE; MOLECULAR SIZE; MOUSE; NEUROBLASTOMA; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; PATHOGENESIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SPONGE (PORIFERA); STRUCTURE ACTIVITY RELATION;

EID: 0033815037     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.10.1519     Document Type: Review

References (70)

1. A sketch of Alzheimer's disease histopathology
2. The neurobiology and pharmacotherapy of Alzheimer's disease
3. Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside the neurofibrillary tangles and neuritic plaques
4. Paired helical filaments have a wide range of widths with similar helical periods
5. Tau protein in normal and Alzheimer's disease brain: An update
6. The tau proteins in Alzheimer's disease
7. Tau protein pathology in Alzheimer's disease and related disorders
8. Tau protein pathology in neurodegenerative disease
9. The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like tau phosphorylation
10. Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders
11. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease
12. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38 and glycogen synthase kinase 3-beta
13. Alterations in content and phosphorylation state of cytoskeletal proteins in the sciatic nerve during ageing and Alzheimer's disease
14. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease
15. Tau phosphatases
16. Multiple forms of phosphatase from human brain: Isolation and partial characterization of Affi-Gel blue binding phosphatases
17. Inhibition of neurofibrillary degeneration: A rational promising therapeutic target
18. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5
19. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease
20. Glycogen synthase 3-beta is identical to tau protein kinase I generating several epitopes of paired helical filaments
21. Identifiaction of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain
22. cAMP-dependent protein kinase phosphorylation on tau Alzheimer's disease
23. Protein kinase C and calcium/calmodulin-dependent protein kinase II phosphorylate three repeat and four repeat tau isoforms at different rates
24. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer's disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase
25. Nuclear glycogen and glycogen synthase kinase 3
26. Expression analysis of glycogen synthase kinase-3 in human tissues
27. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis
28. The role of glycogen synthase kinase 3 beta in insulin-stimulated glucose metabolism
29. The role of GSK-3 beta in regulating neuronal differentiation in Xenopus laevis
30. Glycogen synthase kinase-3β regulates axonal outgrowth in cultured neurons
31. HIV-1 tat-mediated activation of GSK-3β contributes to tat-mediated neurotoxicity
32. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3β transgenes
33. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer's disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase
34. Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: Analysis of tau protein
35. Phosphorylation of tau by glycogen synthase kinase-3β affects the ability of tau to promote microtubule self-assembly
36. β Phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones
37. Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer's disease neurofibrillary changes
38. Role of the pyrrolidine ring of proline in determining the substrate specificity of cdc2 kinase or cdk5
39. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal cdk5 activator
40. p35, the neuronal-specific activator of cyclin dependent kinase 5 (cdk5) is degradated by the ubiquitin-proteasome pathway
41. ATP-sited directed inhibitors of cyclin-dependent kinases
42. Analysis of the expression, distribution and function of cyclin dependent kinase 5 (cdk5) in developing cerebellar macromolecules
43. Alzheimer's disease: Relationship between muscarinic cholinergic receptors, β-amyloid and tau proteins
44. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Ab
45. Activation of tau protein kinase I/glycogen synthase kinase-3b by amiloid b peptide (25-35) enhances phosphorylation of tau in hippocampal neurons
46. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration
47. Inhibition of tau phosphorylating protein kinase cdk5 prevents b-amyloid-induced neuronal death
48. Lithium at 50: Have the neuroprotective affects of this unique cation been overlooked?
49. Potential therapeutic targets for Alzheimer's disease
50. Emerging strategies for the treatment of Alzheimer's disease at the millennium
51. An assay for glycogen synthase kinase 3 (GSK-3) for use in crude cell extracts
52. Peptide substrate suitable for assaying glycogen synthase kinase-3 in crude cell extracts
53. Starvation induces tau phosphorylation in mouse brain: Implications for Alzheimer's disease
54. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5
55. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells
56. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons
57. Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations
58. A structure-based library approach to kinase inhibitors
59. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity
60. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent
61. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
62. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
63. ATP site-directed competitive and irreversible inhibitors of protein kinases
64. Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors
65. Involvement of tau protein kinase I/GSK-3 in Alzheimer's disease pathogenesis
66. Involvement of tau protein kinase in amyloid-β-induced neurodegeneration
67. An approach to Alzheimer's disease with TPK 1
68. Tau protein kinase 1/GSK-3b and acetylcholine metabolism
69. Elisa-quantitation of phosphorylated tau protein in the Alzheimer's disease brain
70. Development in the research of molecular mechanism of Alzheimer's disease